Department of Medical Microbiology, Hamidiye Faculty of Medicine, University of Health Sciences, Istanbul, Turkey.
Department of Infectious Diseases and Clinical Microbiology, Bakırköy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
Parasitol Res. 2024 Oct 5;123(10):340. doi: 10.1007/s00436-024-08363-2.
According to WHO, between 2000 and 2021, there were approximately 247 million malaria cases and 627,000 deaths globally, with the majority of cases occurring in sub-Saharan Africa. In Turkey, indigenous P. vivax malaria was a major public health problem until its eradication was achieved in 2010. Although indigenous malaria transmission has been significantly reduced since 2010, the country is challenged with imported malaria due to increasing global travel and migration from endemic regions. In this study, all imported malaria cases admitted to Dr. Sadi Konuk Research and Training Hospital, Istanbul, between 2018 and 2023 were included. DNA extraction was performed using archived slides and EDTA blood samples. Real-time PCR was performed to identify samples at the species level using previously reported primers and probes. In addition, all available patient demographics are presented. During the six years between 2018 and 2023, 157 patients were diagnosed with imported malaria. According to the real-time PCR results, 149 cases were P. falciparum (94.9%), five cases were P. vivax (3.2%), two cases were P. ovale (1.3%), and one case was P. malariae (0.6%). The male/female ratio among diagnosed patients was 2.34 (110♂/47♀) among diagnosed patients. Plasmodium falciparum was detected in patients from all African regions, whereas P. vivax was detected only in patients from Liberia and Djibouti. Although malaria cases in Turkey have significantly decreased due to elimination efforts and effective public health interventions, the recent increase in both imported and indigenous cases, as well as the presence of suitable vector species in the country, indicates that malaria still remains a serious public health problem for Turkey.
根据世界卫生组织的数据，在 2000 年至 2021 年间，全球约有 2.47 亿疟疾病例和 62.7 万人死亡，其中大多数病例发生在撒哈拉以南非洲地区。在土耳其，直到 2010 年消除了本土间日疟原虫疟疾，它才成为一个主要的公共卫生问题。尽管自 2010 年以来，本土疟疾传播已经显著减少，但由于从流行地区的全球旅行和移民增加，该国仍面临输入性疟疾的挑战。在这项研究中，纳入了 2018 年至 2023 年期间在伊斯坦布尔 Sadi Konuk 研究和培训医院收治的所有输入性疟疾病例。使用存档的载玻片和 EDTA 血样进行 DNA 提取。使用之前报道的引物和探针在物种水平上进行实时 PCR 以鉴定样本。此外，还提供了所有可用的患者人口统计学资料。在 2018 年至 2023 年的六年期间，诊断出 157 例输入性疟疾病例。根据实时 PCR 结果，149 例为恶性疟原虫（94.9%），5 例为间日疟原虫（3.2%），2 例为卵形疟原虫（1.3%），1 例为三日疟原虫（0.6%）。诊断患者中的男/女比例为 2.34（110♂/47♀）。恶性疟原虫在来自所有非洲地区的患者中均有检出，而间日疟原虫仅在来自利比里亚和吉布提的患者中检出。尽管由于消除努力和有效的公共卫生干预，土耳其的疟疾病例已显著减少，但近期输入性和本土性病例的增加，以及该国适宜媒介物种的存在，表明疟疾仍然是土耳其的一个严重公共卫生问题。
